Seeking Alpha

candooman

candooman
Send Message
View as an RSS Feed
View candooman's Comments BY TICKER:
Latest  |  Highest rated
  • Ocata Therapeutics' (OCAT) CEO Paul Wotton on Q2 2015 Results - Earnings Call Transcript [View article]
    A year ago, when Dr Paul Wotton was hired, the price of the stock was around 8 cents. Today it is (pre-reverse split) at 3.75 cents, a 53% drop. Dr Wotten, are you listening? Board members, are you looking for a replacement?

    I hope none of the researchers are thinking of jumping ship because, if anyone does, the stock could easily plunge to $1 or less.
    Aug 7, 2015. 11:42 AM | 2 Likes Like |Link to Comment
  • Ocata Therapeutics' (OCAT) CEO Paul Wotton on Q2 2015 Results - Earnings Call Transcript [View article]
    This 2nd Qtr CC report is mostly a REHASH of the 1st Qtr Report. The progress in proceeding with the Ph 2 trials is going at an agonizing GLACIAL speed. Hence, the stock price is tanking. We are now at an equivalent of 4 cents before the reverse split. Under Gary Rabin, we would be almost finished with the Ph 2 trials by now... and get the FDA approval by 2017 instead of 2019. The Ph 2 trials is the same as the Phase 1/2b except for the 'placebo' person instead of just 'the other eye' as control, so why is it taking so long to get started?

    Dr Paul Wotton seem to be so scared of making a mistake, he seems to have zero sense of urgency. Does he know what he is doing? Where did they find him?
    Aug 7, 2015. 02:36 AM | 1 Like Like |Link to Comment
  • Ocata Therapeutics Provides Corporate Update for the Second Quarter of 2015 [View article]
    They are repeating information from their past Investor Presentations only, nothing new here other than a few numbers. They do not seem to move on enrollment of patients for the Phase 2. They keep stating it will happen in the 2H.......so is December their target in the 2H? I am afraid to listen to their presentation on Sept 4 because Paul Wotton may say the same things he just said today. Please surprise us Mr Wotton.
    Aug 6, 2015. 06:21 PM | Likes Like |Link to Comment
  • OraSure Technologies beats by $0.02, beats on revenue [View news story]
    Probably go up significantly at open then back down where it started at close. Reason is, it does not have a blockbuster in its future to sustain it at higher levels.
    Aug 5, 2015. 04:45 PM | Likes Like |Link to Comment
  • Why I Sold Sirius XM After Earnings For A Zero Gain [View article]
    $4 became a barrier after Malone made his famous offer to retail stockholders almost two years ago (?) who deemed the offer as too low. He eventually withdrew his offer and stock price never got past a few cents above $4. I am now wondering when this barrier is going to be broken.... after the summer maybe, when the problems that has nothing to do with SIRI subscriptions -- Greece, China, etc., have been resolved?
    Aug 3, 2015. 05:17 PM | 1 Like Like |Link to Comment
  • Why I Sold Sirius XM After Earnings For A Zero Gain [View article]
    Really? Please provide us with the link. Thanks.
    Jul 30, 2015. 11:07 AM | 1 Like Like |Link to Comment
  • Why I Sold Sirius XM After Earnings For A Zero Gain [View article]
    Bot in right after it was announced in Feb 2009 that Malone had struck a deal with Mel. My lowest was/is (still holding that lot) 11 cents and kept on buying. Sold my losers (bit my ego) and bot more SIRI. Now selling some to buy other stocks.
    Jul 30, 2015. 11:02 AM | Likes Like |Link to Comment
  • Why I Sold Sirius XM After Earnings For A Zero Gain [View article]
    SIRI's bonds was, in 2008, being manipulated by Ergan of Dish, trying to push it BK. Almost got it had Malone not struck a deal with Mel L. You ae confusing Dish Network with Liberty Media.
    Jul 30, 2015. 10:49 AM | 1 Like Like |Link to Comment
  • Wi-Fi In Autos, A Sirius Problem [View article]
    The author you are referring to that had a negative view of SIRIUSXM as you kept buying SIRI stocks at <$1 is Rocco Pandela. I actually like him for he gave me and my friends - and You too - a chance to buy a lot of shares at less than $1.
    Jul 29, 2015. 01:07 PM | 3 Likes Like |Link to Comment
  • Ocata And An Early Stage Biotech Valuation Method [View article]
    That will be too high considering the simplicity of the procedure. Drug companies charge high (based on what the market will bear) because it is an all year treatment not a one time treatment. The recent drug prices that were in the $100,000 range have shocked people, especially doctors and regulators and I can see a backlash coming. DNDN is a good example of a doctors and insurance providers backlash.

    My advice to Paul Wotton -- do not be greedy, price reasonably. Enormous volume of business is what will make the company rich. Ex-CEO Gary Rabin's price of $5000/eye is very reasonable. Cataract surgery is in the $1500 - $3500 range. Lasic surgery is a lot lower. I think $5000 - $7000 is the right range. It is the range that Medicare will easily cover; most of AMD patients will likely be paid under medicare.

    Then there is the competition. StemCell Inc is going after the same market and already starting their Ph 2 Trials -- which OCAT has not done and I do not know what they are waiting for. OCAT completed the last cohort of 200.000 cell patients in November last year 10 months ago. There are a few more companies in Japan going after AMD and SMD treatments, and their FDA's trial protocols are simpler and faster than our FDA. By the time FDA gives OCAT its blessings, other companies would have had theirs.
    Jul 25, 2015. 06:03 PM | Likes Like |Link to Comment
  • Ocata And An Early Stage Biotech Valuation Method [View article]
    You are limiting your calculation to treatment in the US. Canada, Europe, Japan, Korea, to name just a few more countries, can afford the treatment (Gary Rabin estimated costs to around $5000/eye) for their senior citizens. So, add 2 million more.... easily.
    Jul 25, 2015. 05:37 PM | Likes Like |Link to Comment
  • Ocata And An Early Stage Biotech Valuation Method [View article]
    The market development of OCATA's therapy will hopefully mimic that of Lasic surgery. The same Lasic surgeons, with a bit of training, should be easily certified in the procedure. They could most likely use the same facilities and staff they are now using plus the cell syringe and the standard equipment used in cell storage. There are thousands of Lasic Centers in the US and CANADA and the rest of the world.

    In addition, and this perhaps will be even bigger, the Eye Centers that do lens implants to fix Cataract could just as easily be certified. This is because these centers are the one who diagnose Macular Degenaration, recommend treatment and actually can do it. Injecting cells into the retina of the eye is a lot simpler than sucking out a clouded lens and replacing it with a clear lens.

    Both facilities above are well established, requiring little training costs and capital expenditures. Both will be eager to expand their businesses to include OCATA's cell theraphy. I am not sure OCATA's management has this included in their marketing plans..... I sincerely hope they do.
    Jul 25, 2015. 05:19 PM | Likes Like |Link to Comment
  • Neuralstem Wins Patent Infringement Case Vs. StemCell, Inc.; Moves Forward In Spinal Cord Injury [View article]
    IMHO, the fair value of $6 was when Ted Harada was shown to "walk" again and before the results of the last ALS Trials was published and discussed. This was a few months ago. To me, the stock tanked not because of bad trial results but in how the trial was presented. The next Phase Trials will be limited to that subset of patients where the treatment works best and the outcome will be a lot better. The "fair" value will then rise a lot more.
    Jul 25, 2015. 04:17 PM | 4 Likes Like |Link to Comment
  • Fluor Corp: Here's A Chance To Own A Quality Name [View article]
    Historically, when crude oil prices tank.... as it has done and is doing now, FLR and other engineering/contractor companies, shares tank as well. With this nuclear deal with Iran and the coming flood of crude oil into the market, oil prices will sink further. This glut of oil in the market will probably last at least 1-2 more years as the world economy had slowed down.... and as energy efficiency in auto and trucks and airplanes improve, thus less oil use. The oil companies have slowed down in their capital expenditures which is the lifeblood of companies like FLR. Hence, FLR shares will not be going anywhere in the next two years.... my prediction. I worked in this industry for more than 35 years and know its up and down history quiet well.
    Jul 14, 2015. 10:34 AM | 3 Likes Like |Link to Comment
  • IRS cracks down on hedge fund tax maneuver [View news story]
    I smell a lawsuit coming and a successful Hedgefund defense -- extending beyond 2016.
    Jul 9, 2015. 09:55 AM | Likes Like |Link to Comment
COMMENTS STATS
379 Comments
622 Likes